<DOC>
	<DOCNO>NCT01626391</DOCNO>
	<brief_summary>The primary purpose study assess safety tolerability TRx0237 take time acetylcholinesterase inhibitor ( i.e. , donepezil , galantamine , rivastigmine ) / memantine treat patient mild moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>Safety Study TRx0237 Patients Already Taking Medications Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Clinical diagnosis cause dementia probable Alzheimer 's disease ( AD ) MiniMental State Examination ( MMSE ) score 1426 ( inclusive ) Cognitive impairment present least 6 month Age ≤90 year Modified Hachinski ischaemic score ≤4 Females , childbearing potential , must use adequate contraception maintain use throughout participation study Patient able read , understand , provide write informed consent Has one identify caregiver able verify daily compliance study drug provide information safety tolerability ; caregiver ( ) must also give consent participate Currently take take acetylcholinesterase inhibitor and/or memantine ; subject must take medication ( ) ≥3 month . The dosage regimen must remain stable ≥6 week must plan remain stable throughout participation study . Able comply study procedure Significant central nervous system disorder Alzheimer 's disease Patients baseline MRI contraindicate metal implant head ( except dental ) , pacemaker , cochlear implant Significant focal intracranial pathology would lead diagnosis probable Alzheimer 's disease Clinical evidence history stroke , transient ischemic attack , significant head injury unexplained recurrent loss consciousness Epilepsy Major depressive disorder , schizophrenia psychotic disorder , bipolar disorder , substance ( include alcohol ) relate disorder Resides hospital continuous care facility History swallow difficulty Pregnant breastfeed History significant hematological abnormality current acute chronic clinically significant abnormality Abnormal serum chemistry laboratory value Screening deem clinically relevant investigator Clinically significant cardiovascular disease abnormal assessment Preexisting current sign symptom respiratory failure Concurrent acute chronic clinically significant immunologic , renal , hepatic , endocrine disease ( adequately treat ) and/or unstable major disease Alzheimer 's disease Prior intolerance methylthioniniumcontaining drug excipients Treatment currently within 3 month Baseline follow medication ( unless otherwise note ) : Tacrine Anxiolytics and/or sedatives/hypnotics ( exception : sedation MRI occasional shortacting benzodiazepine , chloral hydrate , zolpidem need bedtime ) Antipsychotics ( clozapine , chlorpromazine , thioridazine , ziprasidone ) Carbamazepine Drugs associate methaemoglobinaemia ( e.g. , dapsone , local anesthetic benzocaine use chronically , primaquine relate antimalarial , sulfonamide ) Warfarin ( Coumadin derivates phenprocoumon ) Current prior participation clinical trial drug , biologic , device last dose receive within 28 day prior Baseline</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>TRx0237</keyword>
	<keyword>Safety Study</keyword>
	<keyword>AD</keyword>
</DOC>